Results for "consumer data right"
221-230 of 513 results for 'consumer data right'
No longer 'once in a blue moon': bluewashing risks and challenges can't be ignored
In this Insight, we explain why companies should carefully consider their representations about human rights and other social issues, and how to manage associated bluewashing risk. ...
Guide to addressing ESG impacts in generative AI deployment
This guide outlines key ESG risks and impacts companies deploying AI should consider, the questions they should be asking, and what to do in response. ...
Upcoming review of Australia’s patents system
The Australian Government has launched a review of the accessibility of patents for small and medium sized enterprises (SMEs), which follows the phasing-out of the innovation patent system in Australia. ...
Metaverse, VR and AR: what you need to know
The digital world is rapidly transforming and, with the metaverse and other virtual technologies coming to prominence, this transformation is only going to accelerate. To stay ahead of the curve, businesses need to understand what's ahead, the coming changes and what these mean in practice. ...
Have your say: government opens consultation on ADM and AI regulatory frameworks
The Department of the Prime Minister and Cabinet is inviting responses to its recently released issues paper (Issues Paper) to inform future digital economy regulation in the areas of automated decision making (ADM) and artificial intelligence (AI). ...
Beware the perils of false patent marking
Patent marking is a useful way of notifying the public and potential infringers that monopoly rights exist or are pending in a product. However, falsely marking a product as 'patented' or 'patent pending' is fraught with danger. ...
Fool's gold – how packaging can be misleading or deceptive
The Federal Court has ruled that adopting distinctive branding may not be enough to get a trader out of hot water if the get-up of the trader's products is similar to somebody else's. ...
PBS process proving a headache for migraine medications
Challenging a PBAC decision is not straightforward. We take a look at the available options and examine the alleged delays in listing migraine treatments Emgality and Ajovy on the PBS. ...
Do the Corner's trade marks live up to their reputation?
Australian courts must often decide whether two trade marks are 'deceptively similar'. A recent Full Federal Court decision emphasises that this deceptive similarity must arise from the resemblance of the marks themselves — not from their actual use or reputation. ...
Combe International Ltd v Dr August Wolff: deceptive similarity where it counts
IP Australia, the Federal Court and the Full Federal Court have considered whether the trade marks VAGISIL and VAGISAN are deceptively similar. The final answer has now been handed down by the Full Federal Court. We take a look at the decision and what it tells us about deceptive similarity. ...